Shire posts strong Q1 results
This article was originally published in Scrip
Executive Summary
Shire has beaten analyst expectations for the first quarter, with product sales increasing by 9% (13% in constant currencies) and total revenues up by 11% (15% in constant currencies), driven by strong sales of ADHD drug Vyvanse and orphan drug Cinryze